See more : Medacta Group SA (MEDGF) Income Statement Analysis – Financial Results
Complete financial analysis of Quotient Limited (QTNT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Quotient Limited, a leading company in the Medical – Devices industry within the Healthcare sector.
- Krishna Capital & Securities Limited (KRISHNACAP.BO) Income Statement Analysis – Financial Results
- Kodama Chemical Industry Co.,Ltd. (4222.T) Income Statement Analysis – Financial Results
- Maruwa Co., Ltd. (5344.T) Income Statement Analysis – Financial Results
- 10X Capital Venture Acquisition Corp. III (VCXB) Income Statement Analysis – Financial Results
- RecycLiCo Battery Materials Inc. (AMYZF) Income Statement Analysis – Financial Results
Quotient Limited (QTNT)
About Quotient Limited
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ SDS Microarray that is designed as a serological disease screening microarray comprised assays to detect cytomegalovirus and Syphilis; MosaiQ MDS Microarray that is designed as a molecular disease screening microarray test for donor red cells or source plasma; MosaiQ IH Microarray as a blood grouping microarray; MosaiQ Autoimmune Microarray; MosaiQ COVID-19; and MosaiQ IH3 Microarray. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 38.51M | 43.38M | 32.66M | 29.13M | 24.73M | 22.23M | 18.52M | 18.41M | 19.76M | 14.37M | 12.22M | 10.03M |
| Cost of Revenue | 23.57M | 20.07M | 17.80M | 17.23M | 10.47M | 10.84M | 9.66M | 9.76M | 8.41M | 7.17M | 6.75M | 5.63M |
| Gross Profit | 14.95M | 23.31M | 14.86M | 11.90M | 14.26M | 11.38M | 8.86M | 8.65M | 11.35M | 7.20M | 5.47M | 4.41M |
| Gross Profit Ratio | 38.80% | 53.72% | 45.49% | 40.86% | 57.66% | 51.21% | 47.86% | 46.96% | 57.45% | 50.11% | 44.77% | 43.91% |
| Research & Development | 58.69M | 54.17M | 53.74M | 50.68M | 51.20M | 57.06M | 28.78M | 19.22M | 8.07M | 2.62M | 1.75M | 1.70M |
| General & Administrative | 49.06M | 41.80M | 31.95M | 31.55M | 25.70M | 22.72M | 26.10M | 16.39M | 9.47M | 6.82M | 6.01M | 5.35M |
| Selling & Marketing | 11.02M | 9.85M | 9.85M | 8.64M | 7.35M | 5.66M | 3.07M | 2.75M | 2.71M | 2.25M | 1.67M | 1.46M |
| SG&A | 60.08M | 51.65M | 41.80M | 40.18M | 33.05M | 28.38M | 29.17M | 19.14M | 12.18M | 9.08M | 7.69M | 6.80M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 118.77M | 105.81M | 95.55M | 90.86M | 84.25M | 85.44M | 57.95M | 38.36M | 20.24M | 11.69M | 9.43M | 8.51M |
| Cost & Expenses | 142.34M | 125.89M | 113.35M | 108.09M | 94.72M | 96.29M | 67.61M | 48.12M | 28.65M | 18.86M | 16.18M | 14.13M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 57.00K | 87.00K | 0.00 |
| Interest Expense | 31.95M | 25.92M | 23.86M | 20.02M | 15.37M | 9.90M | 4.15M | 2.32M | 1.08M | 291.00K | 427.00K | 312.00K |
| Depreciation & Amortization | 7.42M | 8.62M | 12.28M | 12.77M | 10.41M | 9.46M | 2.95M | 1.68M | 622.00K | 691.00K | 989.00K | 980.00K |
| EBITDA | -84.80M | -72.01M | -65.98M | -72.56M | -57.22M | -65.71M | -26.78M | -55.07M | -8.47M | -3.73M | -3.06M | -3.33M |
| EBITDA Ratio | -220.17% | -165.99% | -202.04% | -249.05% | -231.35% | -295.61% | -144.60% | -299.15% | -42.86% | -25.97% | -25.02% | -33.18% |
| Operating Income | -92.22M | -82.51M | -80.69M | -78.96M | -69.99M | -74.06M | -49.09M | -29.71M | -8.89M | -4.49M | -3.96M | -4.10M |
| Operating Income Ratio | -239.43% | -190.20% | -247.09% | -271.01% | -282.99% | -333.19% | -265.03% | -161.42% | -45.01% | -31.25% | -32.44% | -40.85% |
| Total Other Income/Expenses | -31.95M | -24.04M | -21.42M | -26.39M | -13.00M | -11.01M | 15.21M | -29.35M | -1.27M | -223.00K | -509.00K | -522.00K |
| Income Before Tax | -124.17M | -106.54M | -102.11M | -105.34M | -82.99M | -85.07M | -33.88M | -59.06M | -10.17M | -4.71M | -4.47M | -4.62M |
| Income Before Tax Ratio | -322.40% | -245.61% | -312.69% | -361.58% | -335.55% | -382.73% | -182.91% | -320.83% | -51.46% | -32.80% | -36.61% | -46.05% |
| Income Tax Expense | 961.00K | 1.93M | 661.00K | 44.00K | -649.00K | -1.11M | 19.36M | -27.03M | -197.00K | 68.00K | -82.00K | -210.00K |
| Net Income | -125.13M | -108.47M | -102.77M | -105.39M | -82.34M | -85.07M | -33.88M | -59.06M | -10.17M | -4.71M | -4.47M | -4.62M |
| Net Income Ratio | -324.89% | -250.05% | -314.71% | -361.73% | -332.92% | -382.73% | -182.91% | -320.83% | -51.46% | -32.80% | -36.61% | -46.05% |
| EPS | -49.11 | -47.35 | -57.41 | -76.82 | -80.65 | -120.90 | -69.29 | -159.91 | -22.13 | -13.12 | -12.45 | -12.86 |
| EPS Diluted | -49.11 | -47.35 | -57.41 | -76.82 | -80.65 | -120.90 | -69.29 | -159.91 | -22.13 | -13.12 | -12.45 | -12.86 |
| Weighted Avg Shares Out | 2.55M | 2.29M | 1.79M | 1.37M | 1.02M | 703.64K | 488.95K | 369.34K | 459.41K | 359.41K | 359.41K | 359.41K |
| Weighted Avg Shares Out (Dil) | 2.55M | 2.29M | 1.79M | 1.37M | 1.02M | 703.64K | 488.95K | 369.34K | 459.41K | 359.41K | 359.41K | 359.41K |
Quotient (QTNT) Reports Q2 Loss, Tops Revenue Estimates
Quotient Limited (QTNT) CEO Manuel Méndez on Q2 2022 Results - Earnings Call Transcript
Quotient Limited Announces receipt of Note Holders Consents to Indenture Amendments That Extend Maturity, Defer Principal Payments on 12% Senior Secured Notes
Quotient Limited Announces Appointment of Chief Financial Officer
Quotient Limited Announces Appointment of Chief Commercial Officer
Is the Options Market Predicting a Spike in Quotient (QTNT) Stock?
QTNT Stock Price: Why It Increased Over 16%
Why Shares of Quotient Limited Soared Friday
Quotient Limited Provides Update on CE Marking Progress of the MosaiQ™ Expanded Immunohematology Microarray
Quotient Limited Announces Christian Albrich as Chief People Officer
Source: https://incomestatements.info
Category: Stock Reports